AbbVie (ABBV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

AbbVie (NYSE:ABBV) issued its earnings results on Friday. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.04, Bloomberg Earnings reports. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The firm had revenue of $7.74 billion for the quarter, compared to analysts’ expectations of $7.53 billion. During the same quarter last year, the business earned $1.20 earnings per share. The business’s revenue was up 13.9% on a year-over-year basis. AbbVie updated its FY18 guidance to $7.33-7.43 EPS and its Q1 guidance to $1.77-1.79 EPS.

Shares of AbbVie (NYSE ABBV) traded up $14.91 during mid-day trading on Friday, reaching $123.21. The company had a trading volume of 19,317,755 shares, compared to its average volume of 4,580,000. AbbVie has a 12 month low of $59.27 and a 12 month high of $125.86. The stock has a market capitalization of $223,450.00, a price-to-earnings ratio of 29.91, a price-to-earnings-growth ratio of 1.26 and a beta of 1.53. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.

In related news, insider Henry O. Gosebruch sold 18,300 shares of the firm’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $90.55, for a total value of $1,657,065.00. Following the completion of the sale, the insider now owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Timothy J. Richmond sold 87,040 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the completion of the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at approximately $11,136,467.10. The disclosure for this sale can be found here. Insiders sold 494,676 shares of company stock valued at $47,237,938 in the last ninety days. 0.23% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in ABBV. Vanguard Group Inc. lifted its position in AbbVie by 3.3% during the second quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after buying an additional 3,706,941 shares during the period. Janus Henderson Group PLC lifted its position in AbbVie by 1,949.7% during the second quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after buying an additional 3,646,510 shares during the period. Orbis Allan Gray Ltd lifted its position in AbbVie by 35.7% during the second quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after buying an additional 3,340,038 shares during the period. Capital Research Global Investors lifted its position in AbbVie by 1.2% during the second quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after buying an additional 2,130,919 shares during the period. Finally, BlackRock Inc. lifted its position in AbbVie by 2.0% during the second quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after buying an additional 1,864,418 shares during the period. 69.22% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on ABBV shares. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 target price on the stock in a report on Tuesday, October 17th. BidaskClub cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 25th. Vetr upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $113.08 target price on the stock in a report on Wednesday, December 20th. Credit Suisse Group set a $98.00 target price on shares of AbbVie and gave the stock a “hold” rating in a report on Monday, January 22nd. Finally, Cowen upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $91.17 to $105.00 in a report on Wednesday, October 11th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. AbbVie presently has an average rating of “Buy” and a consensus target price of $102.57.

ILLEGAL ACTIVITY NOTICE: This story was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/26/abbvie-abbv-announces-earnings-results-beats-estimates-by-0-05-eps.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Earnings History for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply